Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Apyx Medical CorporationNASDAQ: APYX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $632K (cash outflow) fell 16.5% year over year, ahead of the -31.6% change in trailing-twelve-month free cash flow. Sequentially, it fell 77.5% from the prior quarter. Over 3 fiscal years it compounded at -24.6% a year.
Context
- Free cash flow amounted to 17.2% of revenue in FY2025, down 21.8 pp from a year earlier.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -16.5% holds above the trailing-twelve-month pace of -31.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (9.12M) USD
- Year-over-year change
- +51.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.12M) | +51.4% |
| FY2024 | 2024-12-31 | (18.77M) | -224.6% |
| FY2023 | 2023-12-31 | (5.78M) | +72.8% |
| FY2022 | 2022-12-31 | (21.29M) | -90.6% |
| FY2021 | 2021-12-31 | (11.17M) | — |
Free Cash Flow vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 free cash flow of $8.99M is the 6th largest of the 8 companies compared; the peer median is $27.58M.
- Its year-over-year change of -31.6% is the 7th highest of 8, against a peer median of +3.9%.
- Free cash flow amounts to 16.1% of revenue for APYX, versus a peer median of 75.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $46.44M | +3.9% | +15.0% | 904.6% | |
| LTM Mar 2026 | $37.1M | -4.4% | -21.2% | 107.9% | |
| LTM Mar 2026 | $30.75M | -34.2% | +18.9% | 42.5% | |
| LTM Mar 2026 | $27.58M | +1.6% | -9.4% | 48377.2% | |
| LTM Mar 2026 | $26.52M | +21.6% | +10.1% | — | |
| LTM Mar 2026 | $8.99M | -31.6% | -24.6% | 16.1% | |
| LTM Mar 2026 | $7.77M | +182.7% | — | 6.4% | |
| LTM Mar 2026 | $6.97M | +498.5% | +5.2% | 9.3% | |
| Peer median (excluding APYX) | $27.58M | +3.9% | +7.6% | 75.2% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.2M) | (23.28M) | (18.85M) | (23.56M) | (11.11M) |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.09M | 6.7M | 5.11M | 4.01M | 2M |
| Change in Working Capital | (1.84M) | (5.22M) | 5.54M | (1.25M) | (1.59M) |
| Accounts Receivables | (4.9M) | 1.92M | 3.97M | (2.04M) | (1.32M) |
| Inventory | (2.86M) | (5.57M) | 1.46M | 2.26M | (1.07M) |
| Accounts Payables | 1.15M | 67K | 25K | (63K) | 355K |
| Other Working Capital | 4.76M | (1.63M) | 88K | (1.41M) | 446K |
| Other Non-Cash Items | 603K | 628K | 2.25M | 2.15M | 2.04M |
| Operating Cash Flow | (10.45M) | (20.28M) | (5.25M) | (18.05M) | (8M) |
| Capital Expenditures | (723K) | (1.01M) | (533K) | (722K) | (1.11M) |
| Acquisitions (Net) | 195K | 0 | 7.41M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (195K) | 0 | (147K) | 0 | 0 |
| Investing Cash Flow | (723K) | (1.01M) | 6.73M | (722K) | (1.11M) |
| Debt Repayment | (238K) | (148K) | 35.04M | (20K) | (20K) |
| Common Stock Issued | 67K | 365K | 2.72M | 7M | 9.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 195K | 0 | (5.59M) | (235K) | 60K |
| Financing Cash Flow | 24K | 217K | 32.17M | 6.75M | 9.58M |
| Effect of Forex Changes | 103K | 395K | (191K) | 113K | (466K) |
| Net Change in Cash | (11.05M) | (20.68M) | 33.46M | (11.91M) | (1K) |
| Free Cash Flow | (11.17M) | (21.29M) | (5.78M) | (18.77M) | (9.12M) |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.